The CID Chrono™ cobalt-chromium alloy carbofilm-coated coronary stent system

Gabriella Visconti, Amelia Focaccio, Davide Tavano, Flavio Airoldi, Carlo Briguori

Research output: Contribution to journalArticle

Abstract

Background: In an attempt to improve the stent's safety, development of bare metal stents (BMS) continues, with new materials and geometry. Chrono™ (CID, Italy) is a thin strut cobalt-chromium (Co-Cr) stent combining the clinical benefits of the bio- and haemo-compatible Carbofilm™ coating. Methods: We assessed the safety and efficacy of percutaneous coronary interventions (PCI) using the new Co-Cr Chrono™ stent in patients undergoing elective PCI for de novo lesions in native coronary vessels. The patients were followed for 12 months for the occurrence of major cardiac events (MACE, defined as death, myocardial infarction, repeat PCI and bypass surgery). Patients with complex (B2/C) lesions were compared to those with non-complex lesions (A/B1). Results: A total of 340 consecutive patients were analysed: 155 patients with complex lesions (Complex group) and 185 patients with non-complex lesions (Non-complex group). Dual antiplatelet therapy was maintained > 1 month in 21% of patients in both Complex and Non-complex group. Stent length was longer in the Complex group (25 ± 10 mm versus 17 ± 6 mm; p <0.001). Stent diameter <3.0 mm was most frequent in the Complex group (35.5% versus 27.5%; p <0.05). During the 12-month follow-up period MACE occurred in 10.6% of the global population (12.3% in the Complex group and 9.2% in the Non-complex group; p = 0.43). Repeat PCI was most frequent in the Complex group (9.7% versus 3.8%; p = 0.044). The incidence of definite and probable stent thrombosis (ARC criteria) was 1.29% in the Complex group and 1.08% in the Non-complex group (p = 1.0). Conclusions: Implantation of the Co-Cr Chrono™ stent results in a good safety and efficacy for both complex and non-complex de-novo coronary artery lesions.

Original languageEnglish
Pages (from-to)199-204
Number of pages6
JournalInternational Journal of Cardiology
Volume149
Issue number2
DOIs
Publication statusPublished - Jun 2 2011

Fingerprint

Chromium Alloys
Stents
Percutaneous Coronary Intervention
Chromium
Cobalt
Safety
Coronary Vessels
AIDS-Related Complex
Italy
Thrombosis
Metals
Myocardial Infarction

Keywords

  • Outcome
  • Stent
  • Thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The CID Chrono™ cobalt-chromium alloy carbofilm-coated coronary stent system. / Visconti, Gabriella; Focaccio, Amelia; Tavano, Davide; Airoldi, Flavio; Briguori, Carlo.

In: International Journal of Cardiology, Vol. 149, No. 2, 02.06.2011, p. 199-204.

Research output: Contribution to journalArticle

Visconti, Gabriella ; Focaccio, Amelia ; Tavano, Davide ; Airoldi, Flavio ; Briguori, Carlo. / The CID Chrono™ cobalt-chromium alloy carbofilm-coated coronary stent system. In: International Journal of Cardiology. 2011 ; Vol. 149, No. 2. pp. 199-204.
@article{93a8cc6f2ea04a208ee7be5f2dd4fc5e,
title = "The CID Chrono™ cobalt-chromium alloy carbofilm-coated coronary stent system",
abstract = "Background: In an attempt to improve the stent's safety, development of bare metal stents (BMS) continues, with new materials and geometry. Chrono™ (CID, Italy) is a thin strut cobalt-chromium (Co-Cr) stent combining the clinical benefits of the bio- and haemo-compatible Carbofilm™ coating. Methods: We assessed the safety and efficacy of percutaneous coronary interventions (PCI) using the new Co-Cr Chrono™ stent in patients undergoing elective PCI for de novo lesions in native coronary vessels. The patients were followed for 12 months for the occurrence of major cardiac events (MACE, defined as death, myocardial infarction, repeat PCI and bypass surgery). Patients with complex (B2/C) lesions were compared to those with non-complex lesions (A/B1). Results: A total of 340 consecutive patients were analysed: 155 patients with complex lesions (Complex group) and 185 patients with non-complex lesions (Non-complex group). Dual antiplatelet therapy was maintained > 1 month in 21{\%} of patients in both Complex and Non-complex group. Stent length was longer in the Complex group (25 ± 10 mm versus 17 ± 6 mm; p <0.001). Stent diameter <3.0 mm was most frequent in the Complex group (35.5{\%} versus 27.5{\%}; p <0.05). During the 12-month follow-up period MACE occurred in 10.6{\%} of the global population (12.3{\%} in the Complex group and 9.2{\%} in the Non-complex group; p = 0.43). Repeat PCI was most frequent in the Complex group (9.7{\%} versus 3.8{\%}; p = 0.044). The incidence of definite and probable stent thrombosis (ARC criteria) was 1.29{\%} in the Complex group and 1.08{\%} in the Non-complex group (p = 1.0). Conclusions: Implantation of the Co-Cr Chrono™ stent results in a good safety and efficacy for both complex and non-complex de-novo coronary artery lesions.",
keywords = "Outcome, Stent, Thrombosis",
author = "Gabriella Visconti and Amelia Focaccio and Davide Tavano and Flavio Airoldi and Carlo Briguori",
year = "2011",
month = "6",
day = "2",
doi = "10.1016/j.ijcard.2010.01.009",
language = "English",
volume = "149",
pages = "199--204",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - The CID Chrono™ cobalt-chromium alloy carbofilm-coated coronary stent system

AU - Visconti, Gabriella

AU - Focaccio, Amelia

AU - Tavano, Davide

AU - Airoldi, Flavio

AU - Briguori, Carlo

PY - 2011/6/2

Y1 - 2011/6/2

N2 - Background: In an attempt to improve the stent's safety, development of bare metal stents (BMS) continues, with new materials and geometry. Chrono™ (CID, Italy) is a thin strut cobalt-chromium (Co-Cr) stent combining the clinical benefits of the bio- and haemo-compatible Carbofilm™ coating. Methods: We assessed the safety and efficacy of percutaneous coronary interventions (PCI) using the new Co-Cr Chrono™ stent in patients undergoing elective PCI for de novo lesions in native coronary vessels. The patients were followed for 12 months for the occurrence of major cardiac events (MACE, defined as death, myocardial infarction, repeat PCI and bypass surgery). Patients with complex (B2/C) lesions were compared to those with non-complex lesions (A/B1). Results: A total of 340 consecutive patients were analysed: 155 patients with complex lesions (Complex group) and 185 patients with non-complex lesions (Non-complex group). Dual antiplatelet therapy was maintained > 1 month in 21% of patients in both Complex and Non-complex group. Stent length was longer in the Complex group (25 ± 10 mm versus 17 ± 6 mm; p <0.001). Stent diameter <3.0 mm was most frequent in the Complex group (35.5% versus 27.5%; p <0.05). During the 12-month follow-up period MACE occurred in 10.6% of the global population (12.3% in the Complex group and 9.2% in the Non-complex group; p = 0.43). Repeat PCI was most frequent in the Complex group (9.7% versus 3.8%; p = 0.044). The incidence of definite and probable stent thrombosis (ARC criteria) was 1.29% in the Complex group and 1.08% in the Non-complex group (p = 1.0). Conclusions: Implantation of the Co-Cr Chrono™ stent results in a good safety and efficacy for both complex and non-complex de-novo coronary artery lesions.

AB - Background: In an attempt to improve the stent's safety, development of bare metal stents (BMS) continues, with new materials and geometry. Chrono™ (CID, Italy) is a thin strut cobalt-chromium (Co-Cr) stent combining the clinical benefits of the bio- and haemo-compatible Carbofilm™ coating. Methods: We assessed the safety and efficacy of percutaneous coronary interventions (PCI) using the new Co-Cr Chrono™ stent in patients undergoing elective PCI for de novo lesions in native coronary vessels. The patients were followed for 12 months for the occurrence of major cardiac events (MACE, defined as death, myocardial infarction, repeat PCI and bypass surgery). Patients with complex (B2/C) lesions were compared to those with non-complex lesions (A/B1). Results: A total of 340 consecutive patients were analysed: 155 patients with complex lesions (Complex group) and 185 patients with non-complex lesions (Non-complex group). Dual antiplatelet therapy was maintained > 1 month in 21% of patients in both Complex and Non-complex group. Stent length was longer in the Complex group (25 ± 10 mm versus 17 ± 6 mm; p <0.001). Stent diameter <3.0 mm was most frequent in the Complex group (35.5% versus 27.5%; p <0.05). During the 12-month follow-up period MACE occurred in 10.6% of the global population (12.3% in the Complex group and 9.2% in the Non-complex group; p = 0.43). Repeat PCI was most frequent in the Complex group (9.7% versus 3.8%; p = 0.044). The incidence of definite and probable stent thrombosis (ARC criteria) was 1.29% in the Complex group and 1.08% in the Non-complex group (p = 1.0). Conclusions: Implantation of the Co-Cr Chrono™ stent results in a good safety and efficacy for both complex and non-complex de-novo coronary artery lesions.

KW - Outcome

KW - Stent

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=79957451557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957451557&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2010.01.009

DO - 10.1016/j.ijcard.2010.01.009

M3 - Article

C2 - 20138377

AN - SCOPUS:79957451557

VL - 149

SP - 199

EP - 204

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 2

ER -